Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1982 1
1984 1
1986 1
1988 1
1989 2
1991 1
1992 1
1994 1
1995 3
1996 1
1997 3
1998 1
2000 1
2001 1
2002 1
2003 1
2004 1
2005 2
2006 4
2007 4
2008 8
2009 4
2010 1
2011 4
2012 5
2013 7
2014 8
2015 5
2016 11
2017 5
2018 5
2019 8
2020 4
2021 1
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

102 results
Results by year
Filters applied: . Clear all
Page 1
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Del Campo JM, et al. J Clin Oncol. 2019 Nov 10;37(32):2968-2973. doi: 10.1200/JCO.18.02238. Epub 2019 Jun 7. J Clin Oncol. 2019. PMID: 31173551 Free PMC article. Clinical Trial.
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I. Monk BJ, et al. Among authors: del campo jm. J Clin Oncol. 2020 Nov 10;38(32):3753-3762. doi: 10.1200/JCO.20.01164. Epub 2020 Aug 21. J Clin Oncol. 2020. PMID: 32822286 Free PMC article. Clinical Trial.
Self-Consistent Auxiliary Density Perturbation Theory.
Delesma FA, Delgado-Venegas RI, Salahub DR, Del Campo JM, Pedroza-Montero JN, Calaminici P, Köster AM. Delesma FA, et al. Among authors: del campo jm. J Chem Theory Comput. 2021 Nov 9;17(11):6934-6946. doi: 10.1021/acs.jctc.1c00713. Epub 2021 Oct 28. J Chem Theory Comput. 2021. PMID: 34709812
MicroRNAs as prognostic markers in ovarian cancer.
Llauradó M, Majem B, Altadill T, Lanau L, Castellví J, Sánchez-Iglesias JL, Cabrera S, De la Torre J, Díaz-Feijoo B, Pérez-Benavente A, Colás E, Olivan M, Doll A, Alameda F, Matias-Guiu X, Moreno-Bueno G, Carey MS, Del Campo JM, Gil-Moreno A, Reventós J, Rigau M. Llauradó M, et al. Among authors: del campo jm. Mol Cell Endocrinol. 2014 Jun 5;390(1-2):73-84. doi: 10.1016/j.mce.2014.03.006. Epub 2014 Apr 18. Mol Cell Endocrinol. 2014. PMID: 24747602 Review.
Discussion: session 2.
del Campo JM, Sehouli J, Lorusso D. del Campo JM, et al. Future Oncol. 2013 Dec;9(12 Suppl):37-9. doi: 10.2217/fon.13.202. Future Oncol. 2013. PMID: 24195529 No abstract available.
Discussion: session 1.
Sehouli J, del Campo JM, Lorusso D. Sehouli J, et al. Among authors: del campo jm. Future Oncol. 2013 Dec;9(12 Suppl):25-7. doi: 10.2217/fon.13.201. Future Oncol. 2013. PMID: 24195527 No abstract available.
Update on novel therapeutic agents for cervical cancer.
del Campo JM, Prat A, Gil-Moreno A, Pérez J, Parera M. del Campo JM, et al. Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S72-6. doi: 10.1016/j.ygyno.2008.04.016. Epub 2008 Jun 9. Gynecol Oncol. 2008. PMID: 18544460 Review.
102 results